Member Login
  1. Stocks
    2. /
  2. AstraZeneca PLC (LSE: AZN)
    3. /

LSE:AZN (AstraZeneca PLC)

About AZN

AstraZeneca is a biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Respiratory, Inflammation and Autoimmunity (RIA), Cardiovascular and Metabolic Disease (CVMD) and Oncology – as well as in Infection and Neuroscience.
Financial Market Data copyright © 2025 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

    • AstraZeneca PLC (LSE: AZN) Latest News

    Investing Articles

    As Deadline Passes, Will AstraZeneca plc Attract A New Bid From Pfizer Inc?

    | Roland Head

    Roland Head asks whether AstraZeneca plc (LON:AZN) still holds the same attraction for Pfizer Inc.

    Read more »

    Investing Articles

    Is It Too Late To Buy November’s Winners, AstraZeneca plc And Vodafone Group plc?

    | Harvey Jones

    AstraZeneca plc (LON: AZN) and Vodafone Group plc (LON: VOD) have been on a winning streak, Harvey Jones asks whether…

    Read more »

    Investing Articles

    2 Numbers That Could Make AstraZeneca plc A Terrific Turnaround Play

    | Royston Wild

    Royston Wild explains why AstraZeneca plc (LON: AZN) could prove a classic contrarian winner.

    Read more »

    Investing Articles

    Neil Woodford Praises AstraZeneca plc’s Prospects

    | Rupert Hargreaves

    Woodford is excited about AstraZeneca plc's (LON: AZN) future prospects.

    Read more »

    Investing Articles

    AstraZeneca plc: Why $4.20 Is The Magic Number

    | Rupert Hargreaves

    AstraZeneca plc's (LON: AZN) management will be keeping a keen eye on the company's earnings.

    Read more »

    Investing Articles

    Forget About 2015: Why AstraZeneca plc Remains A Spectacular Long-Term Pick

    | Royston Wild

    Royston Wild explains why AstraZeneca plc (LON: AZN) may prove to be a red-hot growth selection.

    Read more »

    Investing Articles

    At What Price Would AstraZeneca plc Be A Bargain Buy?

    | G A Chester

    G A Chester explains his bargain-buy price for AstraZeneca plc (LON:AZN).

    Read more »

    Investing Articles

    My Top 3 Pharmaceutical Stocks For 2015: GlaxoSmithKline plc, AstraZeneca plc And BTG plc

    | Peter Stephens

    GlaxoSmithKline plc (LON: GSK), AstraZeneca plc (LON: AZN) and BTG plc (LON: BTG) could have a great 2015

    Read more »

    Investing Articles

    AstraZeneca plc And GlaxoSmithKline plc Are Strong Buys, But For Very Different Reasons

    | Harvey Jones

    AstraZeneca plc (LON: AZN) and GlaxoSmithKline plc (LON: GSK) have their differences, but there is strength in diversity, says Harvey…

    Read more »

    Investing Articles

    Can AstraZeneca plc Beat The FTSE 100 In 2015?

    | Peter Stephens

    Should you buy shares in AstraZeneca plc (LON: AZN) in expectation of FTSE 100-beating performance next year?

    Read more »

    Investing Articles

    Will AstraZeneca plc Return To Growth As Soon As Next Year?

    | Alan Oscroft

    Guidance at AstraZeneca plc (LON: AZN) has been lifted, so how soon will earnings growth follow?

    Read more »

    Investing Articles

    AstraZeneca plc Lifts Full-Year Guidance In Third-Quarter Results

    | Peter Stephens

    Upbeat quarterly results from AstraZeneca plc (LON: AZN) include an increase in its top and bottom line forecasts for the…

    Read more »